Moderna Insider Cashes In as mRNA Cancer Vaccine Nears Key Readout
Published on 09/17/2026 at 17:03 | Editorial boerse-global.de
Moderna president Stephen Hoge moved to monetize a slice of his stake this week, exercising options over 152,905 shares at $12.21 apiece before selling 80,575 of them on the open market. The Monday and Tuesday trades — 40,294 shares at an average of $144.13, followed by 40,281 at $146.07 — generated roughly $11.7 million. The transactions ran through a Rule 10b5-1 trading plan established on June 15, 2026, the kind of pre-scheduled arrangement that lets executives liquidate compensation components on autopilot. Hoge still holds more than 1.56 million Moderna shares directly, plus additional interests held through trusts and other entities.
Insider sales of this type are routine across biotech and generally signal no shift in management's view of the business. The timing, however, lands squarely in a stretch of heightened investor attention on the company's pipeline.
A 378% Run Built on Clinical Wins
Moderna shares closed at EUR 126.88 in the prior session, capping a year-to-date advance of 378%. The stock is now about 15% below its 52-week high, and in today's trading it added 9.8% to reach EUR 139.42.
The rally rests on tangible clinical progress. Moderna reported last Tuesday that the Phase 3 INTerpath-001 trial met its goals, a disclosure accompanied by a 1.9% share price gain. The study tested the individualized mRNA therapy intismeran autogene alongside Merck's Keytruda in melanoma patients, hitting both the primary endpoint of recurrence-free survival and the secondary endpoint of distant metastasis-free survival.
Should investors sell immediately? Or is it worth buying Moderna?
Earlier Phase 2b data, presented at the ASCO oncology congress, had shown the combination cutting the risk of recurrence or death by 49% versus Keytruda alone. Management has guided toward an interim analysis from the Phase 3 adjuvant melanoma study in the second half of 2026 and has voiced confidence in the outcome. Alicia Zhou, who heads the Cancer Research Institute, called the recent stretch an outstanding year for tumor vaccine research.
A Second Regulatory Front Opens
Oncology is not the only lever. The FDA cleared Moderna's flu shot mFLUSIVA on August 5. In trials, the mRNA vaccine demonstrated roughly 26.6% greater efficacy against laboratory-confirmed infection in adults aged 50 and older compared with conventional flu vaccines. Reviews are ongoing in Europe, Canada and Australia.
The established vaccine franchise is also widening its footprint. South Korea will fold Covid-19 immunization into its regular national program starting October 12, targeting people aged 65 and up, the immunocompromised and nursing home residents. The nationwide campaign will draw on 4.84 million doses of XFG vaccines supplied by Moderna and Pfizer.
The Balance Sheet Still Sets the Terms
None of this erases the operating picture. Moderna remains loss-making with ongoing cash consumption, and a convertible bond issued roughly two weeks ago put dilution risk back on the table. Second-quarter results showed a loss of $1.97 per share on revenue of $145.0 million — a miss on the top line but ahead of market estimates on the bottom line.
For full-year 2026, management is targeting revenue growth of up to 10%, with year-end cash projected between $4.7 billion and $5.2 billion. How quickly the oncology and new vaccine wins convert into dependable revenue streams will determine what the next leg of the story looks like.
Ad
Moderna Stock: New Analysis - 17 September
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
